| Literature DB >> 35484828 |
Yong Wang1, Jiankang Shen1, Rongli Xie1, Dan Tan1, Xiaoli Jin1, Liang Shen2, Jianmin Yuan1.
Abstract
BACKGROUND This study aimed to compare a precision approach to intraoperative nerve block with traditional analgesia to reduce postoperative pain in 120 patients during thyroid surgery. The precision intraoperative technique used 0.3% ropivacaine to block the lower branch of the transverse cervical nerve and the inner branches of the supraclavicular nerve. MATERIAL AND METHODS A total of 120 patients were prospectively enrolled in this study. All patients were randomly and evenly divided into 3 groups. In the precision group, 0.3% ropivacaine was used through the wound during surgery. In the traditional group, a superficial cervical plexus nerve block was performed before surgery. Saline was injected in the control group. The valuation of postoperative pain was assessed using the visual analogue scale (VAS). RESULTS Two hours after surgery, the VAS scores in the precision group, traditional group, and control group were 1.4±0.5, 1.6±0.7, and 2.8±1.0 (P<0.001), respectively. Then, the pain improvement was more significant after 6 h, as the VAS scores in the precision, traditional, and control groups were 1.0±0.5, 1.2±0.6, and 2.6±1.1 (P<0.001), respectively. Twenty-four hours after surgery, the VAS scores in the precision, traditional, and control groups were 0.7±0.3, 0.6±0.4, and 1.9±1.1 (P<0.001), respectively. CONCLUSIONS At a single center, the use of a precision intraoperative ropivacaine nerve block significantly reduced postoperative pain when compared with traditional analgesia for patients undergoing thyroid surgery.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35484828 PMCID: PMC9063454 DOI: 10.12659/MSM.935563
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1(A, B) Intraoperative precision nerve block was administered through the wound for postoperative analgesia. In the precision group, 0.3% ropivacaine (1.5 mL for each nerve) was used through the wound during surgery. At the deep level of the platysma muscle, the ropivacaine was firstly injected upward along the front edge of the sternocleidomastoid muscle to block the lower branch of the transverse cervical nerve, and then was injected along the anterolateral direction of the sternocleidomastoid muscle to block the inner branches of the supraclavicular nerve.
The effect of precision intraoperative ropivacaine nerve block on postoperative pain. The collected clinic-pathological characteristics of enrolled patients were as follows: age, sex, operation time, pathological diagnosis, and scope of operation, and visual analogue scale (VAS) score.
| Precision group | Traditional group | Control group |
| ||
|---|---|---|---|---|---|
| Age | 37.2±10.9 | 35.6±8.7 | 36.8±9.0 | 0.826 | |
| Sex | Male | 9 | 10 | 8 | 0.866 |
| Female | 31 | 30 | 32 | ||
| Operation time | 95.6±15.3 | 101.5±18.3 | 94.3±12.6 | 0.750 | |
| Diagnosis | Benign | 8 | 7 | 7 | 0.946 |
| Malignant | 32 | 33 | 33 | ||
| Scope | Unilateral | 25 | 27 | 25 | 0.865 |
| Bilateral | 15 | 13 | 15 | ||
| VAS | 2 h | 1.4±0.5 | 1.6±0.7 | 2.8±1.0 | <0.001 |
| 6 h | 1.0±0.5 | 1.2±0.6 | 2.6±1.1 | <0.001 | |
| 24 h | 0.7±0.3 | 0.6±0.4 | 1.9±1.1 | <0.001 | |
The effect of precision intraoperative ropivacaine nerve block on visual analogue scale (VAS) scores. The VAS was performed at 2 h, 6 h, and 24 h after surgery was completed. Visual Analogue Score (VAS).
| Time after the surgery | Precision group | Tradition group | Control group |
| ||
|---|---|---|---|---|---|---|
| 2 h | Sex | Male | 1.5±0.6 | 1.7±0.6 | 3.3±1.1 | 0.001 |
| Female | 1.4±0.5 | 1.6±0.5 | 2.6±1.0 | <0.001 | ||
|
| 0.717 | 0.587 | 0.035 | |||
| Diagnosis | Benign | 1.3±0.6 | 1.6±0.6 | 2.6±1.2 | 0.017 | |
| Malignant | 1.4±0.7 | 1.7±0.7 | 2.9±1.1 | <0.001 | ||
|
| 0.821 | 0.651 | 0.726 | |||
| Scope | Unilateral | 1.4±0.6 | 1.5±0.6 | 2.5±0.9 | <0.001 | |
| Bilateral | 1.5±0.6 | 1.7±0.7 | 3.3±1.1 | <0.001 | ||
|
| 0.225 | 0.198 | 0.020 | |||
| 6 h | Sex | Male | 1.1±0.6 | 1.2±0.6 | 2.6±1.1 | 0.005 |
| Female | 1.0±0.5 | 1.1±0.5 | 2.6±1.0 | <0.001 | ||
|
| 0.741 | 0.572 | 0.915 | |||
| Diagnosis | Benign | 1.0±0.5 | 1.1±0.6 | 2.4±1.2 | 0.012 | |
| Malignant | 1.0±0.6 | 1.2±0.5 | 2.7±1.2 | <0.001 | ||
|
| 0.851 | 0.632 | 0.520 | |||
| Scope | Unilateral | 0.9±0.4 | 1.1±0.5 | 2.4±1.0 | <0.001 | |
| Bilateral | 1.1±0.6 | 1.2±0.6 | 2.7±1.2 | <0.001 | ||
|
| 0.362 | 0.542 | 0.261 | |||
| 24 h | Sex | Male | 0.8±0.4 | 0.7±0.5 | 2.0±1.0 | 0.001 |
| Female | 0.7±0.3 | 0.6±0.4 | 1.8±0.9 | <0.001 | ||
|
| 0.861 | 0.675 | 0.545 | |||
| Diagnosis | Benign | 0.7±0.4 | 0.5±0.5 | 1.8±1.0 | 0.010 | |
| Malignant | 0.7±0.4 | 0.6±0.4 | 2.0±1.0 | <0.001 | ||
|
| 0.914 | 0.532 | 0.468 | |||
| Scope | Unilateral | 0.7±0.3 | 0.5±0.4 | 1.8±0.8 | <0.001 | |
| Bilateral | 0.7±0.5 | 0.6±0.4 | 2.0±1.0 | <0.001 | ||
|
| 0.875 | 0.453 | 0.432 |